ReviewJournal of hematology & oncology2025

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Manh-Cuong Vo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.